1.77
+0.04(+2.31%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.76 |
| Day High | 1.9 |
| Day Low | 1.73 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.95 |
| Volume | 877,548 |
| Average Volume | 290,056 |
| Market Cap | 63.63M |
| PE | -3 |
| EPS | -0.59 |
| Moving Average 50 Days | 1.69 |
| Moving Average 200 Days | 1.93 |
| Change | 0.04 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $145.08 as of August 18, 2025 at a share price of $1.77. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $463.35 as of August 18, 2025 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
GlobeNewswire Inc.
Jul 24, 2025 12:53 PM GMT
BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule the
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
GlobeNewswire Inc.
Jul 16, 2025 1:03 PM GMT
BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Jul 15, 2025 8:36 PM GMT
BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the